Royalty Pharma plc (RPRX) Stock Price & How to Invest

Royalty Pharma plc buys the right to receive royalties on approved and development-stage biopharmaceutical products. A university, a research hospital, a small-cap biotech or a large pharmaceutical company owns a royalty on a drug; Royalty Pharma pays a lump sum, sometimes staged across milestones, and thereafter receives a percentage of that drug's top-line sales. The portfolio spans more than 35 marketed therapies and 19 development-stage candidates. In the second quarter of 2026 the largest contributors were Vertex's cystic fibrosis franchise at $194 million of Royalty Receipts, Biogen's Tysabri at $67 million, GSK's Trelegy at $58 million, Johnson & Johnson's Tremfya at $57 million, Roche's Evrysdi at $47 million and Servier's Voranigo at $46 million. Founded in 1996 and public since 2020, the company is incorporated in England and Wales, headquartered in New York, and lists only its Class A ordinary shares on Nasdaq. Until May 16, 2025 it was externally managed and paid a quarterly fee of 6.5% of royalty cash receipts plus 0.25% of security investments; that manager was bought in, and the staff now sit inside the company.

What drives the numbers is the spread between what a royalty costs and what it eventually pays, compounded by redeploying the cash. Royalty Receipts grew 14% to $768 million in the second quarter of 2026 and 13.4% to $1,655 million in the first half, led by Tremfya, Voranigo, Amgen's Imdelltra and Evrysdi, against declines at Promacta (down 75% on US generic entry) and Imbruvica (down 17%). Management raised full-year Portfolio Receipts guidance for the second time in 2026, to $3,400 million to $3,500 million. Because royalties are financial assets rather than inventory, there is almost no cost of goods and no salesforce, so operating and professional payments ran at 4.8% of Portfolio Receipts in the second quarter against 8.9% for all of 2025. Capital deployment supplies the other half of the growth: $2.6 billion in 2025 and $1.1 billion announced through August 4, 2026, funded out of collections rather than dilution. The market is paying roughly $35.3 billion of equity value plus about $8.4 billion of net debt for that stream, which works out near 10 times the receipts guided for this year and about 13.5 times trailing Adjusted EBITDA of roughly $3.2 billion.

Concentration is the first thing to size. Vertex's cystic fibrosis franchise supplied 32% of total income and other revenues in the second quarter of 2026 and 33% across the half, and its $194 million of quarterly Royalty Receipts were flat year on year. That royalty is perpetual in contract but the company models a 2039 to 2041 duration on expected Alyftrek patent expiry. There is also an unresolved dispute with the payor: beginning in the second quarter of 2025 Royalty Pharma did not receive what it believes it is contractually owed on Alyftrek net sales and has commenced the contractual dispute resolution procedures, with any recovery recognised only if the matter resolves in its favour. Individual royalties can also go to zero. Ipsen and Eisai withdrew Tazverik across all indications in March 2026, producing a $69.4 million non-cash impairment and the gross write-off of a $548.3 million financial royalty asset. Promacta receipts fell 75% in the quarter on US generic entry and Imbruvica fell 17%, both real cash declines that the growers merely offset. Reported earnings swing on estimates rather than operations: the provision for changes in expected cash flows was a $268 million charge in the second quarter of 2026 against a $204 million benefit a year earlier, which is why net income attributable to the plc fell to $17.9 million and diluted EPS to $0.04. Leverage of $9.2 billion sits ahead of shareholders and drove $187.3 million of interest expense in the half. Tax is a live question too: the company records no income tax expense today, and it flags the UK's adoption of the Pillar Two 15% global minimum tax rules alongside its own statement that its tax position is not free from doubt.

8 analysts publish price targets on RPRX, averaging $64.75 against a $61.31 price as of August 2026, or +5.6%. The published targets run from $61.00 to $70.00, a narrow spread, and the ratings split 7 buy, 1 hold, 0 sell. Over the last six months there have been 6 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full RPRX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Royalty Pharma plc. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Royalty Receipts are outrunning the headline receipts number. Royalty Receipts, the recurring sales-linked part of the business, rose 14% to $768 million in the second quarter of 2026 and 13.4% to $1,655 million in the first half. The most optimistic published target, $70.00, assumes this works close to its best case.

The case against. Concentration is the first thing to size. The most pessimistic target, $61.00, is roughly what RPRX is worth if this bites instead.

Read the full bull and bear case on RPRX, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Royalty Pharma plc's investor relations page or your broker.

• Revenue (TTM, GAAP): ~$2.54 billion of total income and other revenues for the twelve months to June 30, 2026, against $2,378 million in fiscal 2025, $2,264 million in 2024 and $2,355 million in 2023. GAAP quarterly income was $674 million in the second quarter of 2026, of which $638 million was income from financial royalty assets and $36 million other royalty income. The line is not a sales figure in the ordinary sense: it is the interest component of royalty collections, accreted under the effective interest method off sell-side consensus sales forecasts, so it moves when analysts revise the drugs Royalty Pharma has bought into.
• Portfolio Receipts (the operating measure): $3,254 million in 2025, up 16% from $2,801 million in 2024, and $1,698 million in the first half of 2026, up 8.4% from $1,566.8 million. Royalty Receipts, the sales-linked core, were $3,127 million in 2025 and $1,655 million in the first half of 2026 (up 13.4%). Guidance raised on August 5, 2026 puts full-year Portfolio Receipts at $3,400 million to $3,500 million, with Royalty Receipts growth of 7% to 10% and an assumed ~1% currency tailwind, excluding anything transacted after that date.
• Earnings and EPS: Diluted EPS of $1.86 on a trailing twelve-month basis, from net income attributable to Royalty Pharma plc; GAAP net income was $770.95 million in fiscal 2025 and $858.98 million in 2024. The quarterly path is erratic by design: first-half 2026 diluted EPS was $0.71 on $312.6 million attributable to the plc, but the second quarter alone was $0.04 after a $268 million provision for changes in expected cash flows. Consolidated net income of $549.7 million in the half was reduced by $237.2 million attributable to non-controlling interests before reaching Class A holders.
• Cash flow and Adjusted EBITDA: Net cash provided by operating activities was $1,447 million in the first half of 2026 against $960 million a year earlier, and $2,490 million for full-year 2025. Adjusted EBITDA, defined in the credit agreement as Portfolio Receipts less payments for operating and professional costs, was $736 million in the second quarter and roughly $3.2 billion trailing; Portfolio Cash Flow, after net interest, was $736 million in the quarter and $2,724 million in 2025. Payments for operating and professional costs ran at 4.8% of Portfolio Receipts in the quarter versus 8.9% for all of 2025.
• Balance sheet and capital returns: Cash and equivalents of $812 million at June 30, 2026 against total debt with principal value of $9.2 billion, with the $380 million term loan repaid at maturity in July. Financial royalty assets carried at $17.08 billion within $19.82 billion of total assets, and shareholders' equity of $9.79 billion including $2.95 billion of non-controlling interests. Capital returned in the half: $209 million of dividends and ~$95.6 million of buybacks (2.0 million Class A shares), with ~$1.7 billion left on the $3.0 billion authorisation. Accrued compensation liabilities were $713.2 million.
• Market pricing: Recently ~$61.31 per Class A share against a 52-week range of $34.08 to $62.13, for a market capitalisation of ~$35.25 billion. Share count as of July 31, 2026 was 445.28 million Class A plus 129.72 million Class B, and because Class B carries votes but essentially no economics in the plc (the paired RP Holdings Class B Interests exchange one-for-one into Class A), ~575 million is the economically relevant figure while basic EPS is struck on ~445 million. Trailing P/E of ~32.9 against a forward P/E near 11.4, dividend of $0.235 per quarter (~$0.94 annualised, ~1.5%), and enterprise value of roughly $43 billion, about 13.5 times trailing Adjusted EBITDA.

The ~14 times sales a screener prints comes from dividing a $35.25 billion market cap by $2.54 billion of GAAP revenue, which is the wrong denominator for this structure. Measured against the $3.4 billion to $3.5 billion of Portfolio Receipts guided for 2026, the same market cap is about 10 times, and enterprise value is roughly 13.5 times trailing Adjusted EBITDA. The gap between the trailing P/E near 33 and a forward P/E near 11 is the same effect seen from the earnings side, with non-cash provisions and impairments compressing reported profit while cash collections keep rising.

Other names that sit close to RPRX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get RPRX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so RPRX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where RPRX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

As of August 2026, RPRX trades at roughly 10 times guided 2026 Portfolio Receipts and about 13.5 times trailing Adjusted EBITDA, with a ~1.5% dividend and a $9.2 billion debt stack behind it. The trailing P/E near 33 is mostly an artifact of non-cash re-estimates of royalty cash flows, not a reading of the underlying cash economics.

Whether RPRX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is RPRX a buy or a sell?, and where the stock could go from here in the RPRX stock forecast.

For income investors, whether RPRX pays a dividend and how the payout looks is covered in does RPRX pay a dividend? And to weigh RPRX against a peer, read the full side-by-side comparisons: RPRX vs DRI and RPRX vs BX.